Cardiac
Failure
·
Pathophysiology.
·
Principles of therapy.
·
Individual drugs.
Pathophysiology
1.
Cardiac failure is present when the heart cannot provide all organs with
the blood supply appropriate to demand, i.e. the cardiac output is inadequate.
2.
Cardiac output = Heart rate x Stroke volume.
3.
Factors regulating stroke volume:
a.
Preload: the load on the heart created by the volume of blood injected
into the left ventricle by the left atrium.
b.
Afterload: the load on the contracting ventricle created by the
resistance to the blood injected by the ventricle into the arterial system.
c.
Contractility: the capacity of the myocardium to generate the force
necessary to response to preload and to overcome afterload.
Principles of Drug therapy
1.
Objectives:
a. To
reduce morbidity.
b. To
reduce mortality.
2.
Target of therapy:
a.
Treatment of failing pump: to increase contractility.
b.
Treatment of underlying causes of cardiac failure, e.g. hypertension.
c.
Treatment of associated problems, e.g. atrial fibrillation, pulmonary
edema.
3. Drug
therapy serves to:
a.
increase cardiac output.
b.
reduces myocardial workload and oxygen demand.
4.
Cardiac output can be increased by strengthening the heart or by reducing
the resistance against which it has to work.
5.
Afterload reduction by vasodilators includes more options, and the ACE
inhibitors are the most widely used.
6. The
nitrates also act by partly reducing afterload, but also improve coronary blood
flow.
7.
Classification of drugs:
a.
Reduction of preload: diuretics, nitrates.
b.
Reduction of preload and afterload: ACE inhibitors.
c.
Stimulation of myocardium: digoxin.
8.
Management:
a. Mild
cardiac failure should be treated with a thiazide diuretic, if renal function is
normal.
b. If
not, or if edema persists, the next step is a loop diuretic in lowly daily dose,
e.g. frusemide, to which amiloride can be added to conserve potassium.
c. The
addition of a thiazide, usually metolazone, to a loop diuretic is usually
effective in stimulating a diuresis.
d. All
patients requiring chronic diuretic treatment for heart failure should also now
receive an ACE inhibitor which improve survival even in mild failure.
e. ACE
inhibitors have a diuretic-sparing effect, which improves the patients’
symptoms by maintaining peripheral perfusion, and reducing the neurohumoral
response to excessive diuresis.
f.
An alternative to ACE inhibitors as a vasodilator is isosorbide
mononitrate to which hydralazine may later be combined.
Drugs used in cardiac failure
1.
Diuretics:
a.
Increase salt and water loss, reduce blood volume and lower excessive
venous filling pressure.
b. The
congestive features of edema, in the lungs and periphery, are alleviated.
c.
When the heart is grossly enlarged, cardiac output will also increase.
2.
Nitrates:
a.
Dilate the smooth muscle in venous capacitance vessels, increase the
volume of the venous vascular bed, reduce ventricular filling pressure, thus
decreasing heart wall stretch, and reduce myocardial oxygen.
b.
Glyceryl trinitrate may be given sublingually for acute left ventricular
failure.
c. For
chronic left ventricular failure isosorbide dinitrate or isosorbide mononitrate
may be given by mouth in divided doses
d.
Exercise capacity is improved but tolerance to nitrates may develop with
chronic use.
3.
Reduction of afterload:
a.
Hydralazine relaxes arterial smooth muscle and reduces peripheral
vascular resistance.
b.
Reflex tachycardia, however, limits its usefulness and lupus
erythematosus may be induced.
4. ACE
inhibitors:
a.
Reduce afterload by preventing the conversion of angiotensin I to
angiotensin II, a powerful vasoconstrictor.
b.
Reduce preload, because the formation of aldosterone, and thus retention
of salt and water, is prevented by reduction of angiotensin II.
c. ACE
inhibitors are the only drugs which reduce peripheral resistance without causing
a reflex activation of the sympathetic system.
5.
Digoxin:
a.
Improves myocardial contractility most effectively in the dilated,
failing heart.
b. Ventricular filling is improved.
6. Adjunct drugs:
a. Digoxin: to reduce ventricular rate in atrial fibrillation.
b.
Aspirin / warfarin: anti-platelet and anti-coagulant therapy to reduce risk of
stroke and myocardial infarct.